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Abstract
Background: Patients with subarachnoid haemorrhage (SAH) frequently develop cardiac complications in the acute
phase after the bleeding. Although a number of studies have shown that increased levels of cardiac biomarkers after
SAH are associated with a worse short-term prognosis, no prospective, consecutive study has assessed the association
between biomarker release and long-term outcome. We aimed to evaluate whether the cardiac biomarkers, high-
sensitive troponin T (hsTnT) and N-terminal pro B-type natriuretic peptide (NTproBNP), were associated with poor 1-
year neurological outcome and cerebral infarction due to delayed cerebral ischaemia (CI-DCI).
Methods: In this single-centre prospective observational study, all consecutive patients admitted to our neurointensive
care unit from January 2012 to December 2013 with suspected/verified SAH with an onset of symptoms <72 hours
were enrolled. Blood samples for hsTnT and NTproBNP were collected during three consecutive days following
admission. Patients were followed-up after 1 year using the Glasgow Outcome Scale Extended (GOSE). Poor
neurological outcome was defined as GOSE ≤4.
Results: One hundred and seventy seven patients with suspected SAH were admitted during the study period; 143
fulfilled inclusion criteria and 126 fulfilled follow-up. Forty-one patients had poor 1-year outcome and 18 had CI-DCI.
Levels of hsTnT and NTproBNP were higher in patients with poor outcome and CI-DCI. In multivariable logistic regression
modelling age, poor neurological admission status, cerebral infarction of any cause and peak hsTnT were independently
associated with poor late outcome. Both peak hsTnT and peak NTproBNP were independently associated with CI-DCI.
Conclusion: Increased serum levels of the myocardial damage biomarker hsTnT, when measured early after onset of
SAH, are independently associated with poor 1-year outcome. Furthermore, release of both hsTnT and NTproBNP are
independently associated with CI-DCI. These findings render further support to the notion that troponin release after
SAH is an ominous finding. Future studies should evaluate whether there is a causal relationship between early release
of biomarkers of myocardial injury after SAH and neurological sequelae.
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Background
Patients with subarachnoid haemorrhage (SAH) fre-
quently develop cardiac complications in the acute phase
after the bleeding [1]. A majority of SAH patients develop
electrocardiographic changes, a substantial number have
increased troponin levels and some patients develop an
acute form of stress-induced cardiomyopathy [2-5], usu-
ally presenting as reversible left ventricular apical akinesia
resembling Takotsubo cardiomyopathy [6]. The increased
sympathetic tone with excess of circulating catechol-
amines seen in conjunction with the bleeding is most
likely the cause of cardiac events after SAH [7-11].
A number of studies have shown that early release of
the cardiac biomarkers troponin and B-type natriuretic
peptide are associated with a higher risk of delayed cere-
bral ischaemia (DCI), cerebral infarction (CI), poor out-
come and death [1, 12–15]. This has also been shown for
cardiac complications, such as stress-induced cardiomy-
opathy [15–17]. The functional recovery after SAH is
mainly studied up to 3 months after the bleeding, al-
though many SAH patients improve their functional re-
covery beyond this period [18–20]. There are only a few
studies reporting on the impact of cardiac biomarker re-
lease and cardiac complications on long-term outcome
[21–23].
In recent years, a new method of measuring troponin has
been introduced—high-sensitive troponin T (hsTnT)—with
higher sensitivity and specificity for myocardial injury than
previously used assays [24]. N-terminal pro B-type natri-
uretic peptide (NTproBNP) is a cardiac biomarker with
high sensitivity and specificity for heart failure [25].
Although hsTnT and NTproBNP are increased due to
other conditions in intensive care unit (ICU) patients, such
as sepsis, respiratory failure and renal failure [26, 27],
hsTnT and NTproBNP have a high specificity for cardiac
dysfunction in SAH patients [28–30]. Therefore, the aim of
this study was to evaluate whether hsTnT and/or
NTproBNP are associated with poor 1-year outcome (the
primary aim) and cerebral infarction due to DCI (CI-DCI;
the secondary aim).
Methods
Study design and patient inclusion
This is a single-centre prospective observational study
performed at the neurointensive care unit (NICU) at the
Sahlgrenska University Hospital, Gothenburg. The NICU
is the referral centre for 1.7 million inhabitants in the
Western County Council. All referred patients are inde-
pendently evaluated before admission by a consultant in
neurosurgery. The study was approved by the Gothenburg
Regional Ethics Committee (Ref #348-09). All patients, or
patient’s next of kin, were informed about the study and
were asked for consent. Study inclusion started on 1 Janu-
ary 2012 and ended on 31 December 2013. A brief study
protocol is shown in Fig. 1a. All patients admitted with sus-
pected SAH were eligible for inclusion. Exclusion criteria
were: SAH diagnosis not confirmed, time from onset of
symptoms to admission >72 hours, benign bleeding (e.g.
prepontine non-aneurysmal SAH), and poor prognosis
upon admission without any intervention. Time of onset of
symptoms was obtained from the patients, their next of
kin, or information from ambulance reports. If time of on-
set was unclear, it was defined as the last known time-point
the patient was without symptoms. In all included patients,
hsTnT and NTproBNP were measured on admission and
over the following 3 days. Clinical data were recorded
during ICU stay. Follow-up was performed after 1 year ac-
cording to the Glasgow Outcome Scale Extended (GOSE)
[31]. Follow-up was performed primarily by structured tele-
phone interview with a standardised questionnaire [32] and
secondly by a standardised letter to the patient with a ques-
tionnaire. To avoid bias in loss of follow-up, the follow-
up procedure was standardised by three telephone calls
to the patient. If no contact was achieved, a first letter
was sent; this was followed by two telephone calls to
the patient and two telephone calls to the patient’s next
of kin, which was followed by a reminder letter. If no
contact had been obtained after this procedure, the pa-
tient was declared as lost for follow up. Patients were
A
B
Fig. 1 a Brief study protocol. Blood samples for hsTnT and NTproBNP
were obtained on admission and on the following 3 days. Clinical data
were recorded from admission until ICU discharge. Outcome was
evaluated with the GOSE scale 1 year after admission according to a
standardised procedure (see Methods for details). b Study flow chart.
GOSE Glasgow Outcome Scale Extended, hsTnT High-sensitive troponin
T, ICU Intensive care unit, NTproBNP N-terminal pro B-type natriuretic
peptide, SAH Subarachnoid haemorrhage
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treated according to the Neurocritical care consensus
conference during the study period [33].
Data collection and variable details
The primary outcome variable was GOSE ≤4 1 year after
the bleeding (GOSE 1, dead; GOSE 2, vegetative state;
GOSE 3, hospitalised; GOSE 4, non-independent living)
[31]. The secondary outcome variable was CI-DCI verified
on computed tomography (CT) or magnetic resonance
imaging (MRI). This was defined as the presence of CI on
CT or MRI scan of the brain within 6 weeks after SAH, or
on the latest CT or MRI scan made before death within 6
weeks, not present on the CT or MRI scan between 24
and 48 hours after early aneurysm occlusion. These CT or
MRI findings should not be attributable to other causes
such as surgical clipping, endovascular treatment, ven-
tricular catheter or intraparenchymal haematoma, accord-
ing to the definition by Vergouwen et al. [34]. Primary
predictors were peak levels of hsTnT and NTproBNP de-
fined as the highest level during the first 72 hours after
onset of symptoms. Secondary predictors were the follow-
ing: a) sex, b) age, c) history of cardiovascular disease or
hypertension, d) severity of SAH (graded according to
World Federation of Neurological Surgeons (WFNS)
grading for SAH, dichotomised to WFNS grade 1–3 and
WFNS grade 4–5 [35]), e) CT grading of SAH (defined ac-
cording to modified Fisher scale [36], dichotomised to
modified Fisher 1–3 and modified Fisher 4), f ) treatment
of aneurysm (surgery or embolisation), g) haemodynamic
variables and their management (blood pressure, heart
rate, dose of norepinephrine during the first 3 days after
admission), h) increased cerebral blood flow velocity de-
tected by daily transcranial Doppler (TCD) examinations
(defined as a peak flow velocity >200 cm/s or a diurnal in-
creased velocity >50 cm/s in affected arteries) and i) CT
verified cerebral infarction of any cause (1-year outcome
analysis only).
Biomarker analysis
hsTnT was analysed with the Roche high-sensitive tropo-
nin T assay with a coefficient of variation of 3.4 %.
NTproBNP was analysed with the Elecsys assay (Roche)
on Cobas platform with a coefficient of variation of 3.8 %
as reported from our laboratory.
Statistics
A p value <0.05 was considered significant in the
analyses. Continuous variables were checked for normal
distribution with inspection of histogram distribution
and Shapiro–Wilks test. Student’s T-test was used to
compare means of continuous normally distributed and
Mann–Whitney U test was used to compare medians of
non-normally distributed variables between the two
groups. Fisher’s exact test was used for comparing
incidences between two groups with binary variables.
Spearman rank test was used to test correlation in non-
normally distributed variables. Receiver operating char-
acteristic (ROC) curves were used to determine sensi-
tivity, specificity and cut-off levels for hsTnT and
NTproBNP to predict poor outcome and CI-DCI. For
comparison of levels of hsTnT and NTproBNP over
time between patients with poor and good outcome, a
generalised linear mixed model with gamma regression
was used due to non-normal distribution of hsTnT and
NTproBNP. To determine variables independently as-
sociated with late poor outcome and CI-DCI, multivari-
able logistic regression was used. Variables with a p
value <0.10 on bivariate regression were selected for
the multivariable analysis. All variables included in the
multivariable analysis were checked for co-linearity and
that data were balanced. Due to a limited number of
explanatory variables allowed in the model (≈1 variable
per 10 outcome observations in the poor outcome/CI-
DCI group), a manual forward model building strategy
was used. Variables with a previously described clinical
association with the dependent variable were inserted one
at a time in a reduced model. A variable was maintained
in the model if the new model improved significantly, by
calculating −2 log likelihood change, and if the variable it-
self was significant (p < 0.05). This was repeated until the
best reduced model was obtained. The primary and
remaining secondary predictors were inserted separately
in the reduced model and were considered independently
associated with the dependent variable if it was significant
and a significant better model was obtained. Hosmer and
Lemenshow test was used for goodness of fit and Nagelk-
erke R2 was used for determining explanatory degree
of the model. The software used was IBM SPSS Sta-
tistics version 22.0.
Results
A total of 710 patients were admitted to the NICU
during the study period. One hundred and seventy seven
patients had a suspected SAH. Thirty four patients were
excluded, the main reason was a benign, prepontine
bleeding (n = 19). Study protocol was not adhered to in
four patients. One hundred and thirty nine patients were
eligible for the 1-year follow-up, of whom 13 were lost
in follow-up (Fig. 1b). Of the 126 patients fulfilling study
protocol, 98 patients (78 %) were admitted on day 1, 20 pa-
tients (16 %) were admitted on day 2 and 8 patients (6 %)
were admitted on day 3 after onset of symptoms.
Patient characteristics
Patient characteristics are presented in Table 1. A total
of 74 patients (59 %) were females, 38 patients (30 %)
had WFNS grade 4–5 and 39 patients (31 %) had modi-
fied Fisher grade 4. In 22 patients (17 %) no aneurysm
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was detected. A total of 66 patients (52 %) needed acute
ventricular drainage, 69 patients (55 %) were treated
with embolisation and in 29 patients (23 %) an aneurysm
was clipped. There were no differences regarding sex,
age, surgery/embolisation, WFNS and modified Fischer
grade between patients that were followed up and were
lost to follow-up.
Outcome data
Clinical variables in patients with poor outcome and CI-
DCI are presented in Table 1. At 1-year follow-up, 41
patients (33 %) had poor late outcome. Fourteen patients
died during ICU stay and 7 patients died after ICU dis-
charge but before 1 year. None of the included patients
died during the first 3 days after admission when the
cardiac biomarkers were obtained. Patients with poor out-
come were more likely to have WFNS grade 4–5 (p < 0.001),
modified Fisher grade 4 (p = 0.013) or a cerebral infarction
of any cause (p < 0.001) or caused by DCI (p < 0.001).
They also had a higher age (p = 0.015), heart rate (p =
0.009) and dose of given norepinephrine. A total of 41 (33
%) patients had CT scan verified CI of any cause during
the hospital stay. In 18 (14 %) of these patients, criteria for
CI-DCI were fulfilled. Patients with CI-DCI were more
likely to have increased cerebral blood flow velocities (p =
0.017) and had a higher heart rate (p = 0.028) and dose of
given norepinephrine (p = 0.044).
hsTNT and NTproBNP
Peak levels of hsTnT and NTproBNP were higher in pa-
tients with poor outcome (Fig. 2a and b). hsTnT had its
peak levels on admission followed by a daily decline in
patients with good and poor outcome. There was a close
correlation between peak hsTnT and admission hsTnT
(r = 0.92). NTproBNP had lowest levels on day 1 after
onset of symptoms followed by increased levels on days
2, 3 and 4 in both patients with good and poor outcome
(Fig. 2c and d). Patients with CI-DCI had higher peak
levels of hsTnT (p = 0.045; median 64 ng/l, interquartile
range (IQR) 10–264 ng/l) and NTproBNP (p = 0.011;
median 1395 ng/l, IQR 815–6770 ng/l). Peak levels of
hsTnT were significantly higher in patients with WFNS
grade 4–5, modified Fisher grade 4 and posterior
aneurysm while peak levels of NTproBNP levels were
higher in patients with WFNS grade 4–5 and posterior
aneurysm. Sex, presence of intracerebral haematoma or
history of cardiovascular disease did not have a signifi-
cant impact on hsTnT or NTproBNP levels.
Logistic regression analysis of variables associated with
poor 1-year outcome
Bivariate logistic regression analyses of variables associ-
ated with poor outcome are presented in Table 2. Age,
WFNS grade 4–5, CI of any cause, CI-DCI, modified
Fisher grade 4 and intracerebral haematoma had a p
value <0.10 and are described to have a major impact on
outcome in previous studies [37] and were selected for
inclusion in the reduced model. The best reduced model
consisted of the variables CI of any cause, WFNS grade
4–5 and age (Table 3; Model 1); modified Fisher grade 4
and intracerebral haematoma were not significant to-
gether with the other variables. Both peak hsTnT and
NTproBNP were significant in the bivariate analysis. Sec-
ondary predictors, with a p value <0.10, were high cerebral
blood flow velocity, mean heart rate and dose of given
norepinephrine. In the multivariable analysis, peak hsTnT
was significant when included in the reduced model, while
NTproBNP was not (Table 3; Models 2 and 3). Inclusion
of mean heart rate produced a significantly better model
but was not significant itself (p = 0.056). None of the other
secondary predictors were significant in the multivariable
model.
Logistic regression analysis of variables associated with
CI-DCI
Bivariate logistic regression analyses of variables associ-
ated with CI-DCI are presented in Table 4. TCD de-
tected increased flow velocity and modified Fisher had a
p value <0.10 and are described to have an association
with CI-DCI and were therefore selected for inclusion in
the reduced model. The best reduced model included
TCD detected increased flow velocities only (Table 5;
Model 1). Peak hsTnT and NTproBNP as well as mean
heart rate and dose of given norepinephrine had a p
value <0.10 and were included in the multivariable ana-
lysis. Both peak hsTnT and NTproBNP were significant
when included together with TCD detected increased
flow velocities (Table 5; Models 2 and 3).
Sensitivity and specificity analysis
The best cut-off value of peak hsTnT to predict poor late
outcome was 51 ng/l which had a sensitivity of 56 % and a
specificity of 84 %, while the best cut-off value of peak
NTproBNP was 1230 ng/l which had a sensitivity of 58 %
and a specificity of 71 %. Area under the curve was 0.74
for hsTnT (p < 0.001) and 0.70 for NTproBNP (p < 0.001).
Using the cut-off value 51 ng/l, hsTNT had an odds ratio
of 5.4 in a bivariate logistic regression of poor late out-
come. To predict CI-DCI, the best cut-off value of peak
hsTnT was 69 ng/l which had a sensitivity of 50 % and a
specificity of 82 %. The best cut-off value of peak
NTproBNP was 1250 ng/l with a sensitivity of 66 % and a
specificity of 68 %. Area under the curve was 0.64 (p =
0.047) for hsTnT and 0.69 for NTproBNP (p = 0.011).
Discussion
In the present prospective study, we searched for risk
factors associated with poor 1-year neurological
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outcome and the development of CI-DCI in patients
with SAH. In this aspect, we were particularly interested
in evaluating the role of the cardiac biomarkers indicative
of myocardial injury or heart failure (hsTnT and
NTproBNP) in the early phase after admission. The major
finding was that increased levels of hsTnT, early upon ad-
mission to NICU, were independently associated with
poor late outcome when adjusted for other risk factors
known to affect long-term outcome. In addition, we could
demonstrate that both cardiac biomarkers hsTnT and
NTproBNP were independently associated with CI-DCI.
Patients with poor neurological long-term outcome
were more likely to have higher levels of both hsTnT
and NTproBNP. Furthermore, in the bivariate logistic
regression, peak hsTnT and NTproBNP were both
strongly associated with poor long-term outcome. In
addition, hsTnT was independently associated with poor
1-year outcome when adjusting for important predictors
for poor outcome such as cerebral infarction, poor
neurological status on admission (WFNS grade 4–5) and
age. Using the cut-off value suggested from the ROC
analysis, patients with a peak hsTnT >51 ng/l had a five-
fold increased risk for poor late neurological outcome,
i.e. hsTnT had the same impact in the analysis as poor
neurological status on admission. Although the predict-
ive value of hsTnT to predict poor outcome was only






(n = 126) (n = 41) (n = 18)
Sex
Female 74 (59) 24 (59) 12 (67)
Male 52 (41) 17 (41) 6 (33)
Age, mean ± SD (years) 57 ± 13 61 ± 12 56 ± 14
Medical history
Hypertension 45 (36) 16 (39) 8 (44)
Cardiovascular disease 8 (6) 4 (10) 2 (11)
Other 14 (11) 8 (20) 4 (22)
None 59 (47) 13 (32) 4 (22)
SAH severity grade
WFNS grade 1 50 (40) 5 (12) 4 (22)
WFNS grade 2 29 (23) 8 (20) 7 (39)
WFNS grade 3 9 (7) 6 (15) 1 (6)
WFNS grade 4 20 (16) 11 (27) 5 (28)
WFNS grade 5 18 (14) 11 (27) 1 (6)
Radiological
Modified Fischer grade 1 27 (21) 2 (5) 2 (11)
Modified Fischer grade 2 11 (9) 2 (5) 1 (6)
Modified Fischer grade 3 49 (39) 18 (44) 6 (33)
Modified Fischer grade 4 39 (31) 19 (46) 9 (50)
ICH 12 (10) 7 (17) 1 (6)
Aneurysm position
Anterior communicating artery 33 (26) 10 (24) 3 (17)
Posterior
communicating artery
14 (11) 4 (10) 5 (28)
Middle cerebral artery 21 (17) 9 (22) 1 (6)
Carotid artery 12 (10) 5 (12) 3 (17)
Other anterior circulation 8 (6) 2 (5) 1 (6)
Basilar artery 8 (6) 4 (10) 1 (6)
Other posterior circulation 7 (6) 3 (7) 2 (11)
Not found 23 (18) 4 (10) 2 (11)
Treatment
Acute ventricular drainage 66 (52) 35 (85) 13 (72)
Embolisation 71 (56) 21 (51) 12 (67)
Surgery 30 (24) 11 (27) 3 (17)
None 25 (20) 9 (22) 3 (17)
TCD (flow velocity)
Normal flow velocity 62 (49) 18 (44) 5 (28)
Increased flow velocity 49 (39) 18 (44) 12 (67)
Haemodynamics
SBP on admission, mean ± SD
(mmHg)
149 ± 23 147 ± 26 145 ± 25
MAP on admission, mean ± SD
(mmHg)
102 ± 16 100 ± 16 99 ± 15
Table 1 Patient characteristics (Continued)
HR on admission, mean ± SD
(beats per minute)
72 ± 15 73 ± 16 76 ± 19
SBP meana, mean ± SD (mmHg) 134 ± 13 133 ± 14 133 ± 11
HR meana, mean ± SD
(beats per minute)
64 ± 8 68 ± 9 69 ± 7









Cerebral infarction, any cause 41 (33) 27 (66) 18 (100)
Infarction due to DCI 18 (14) 14 (34) 18 (100)
GOSE
GOSE 1 21 (17) 21 (51) 9 (50)
GOSE 2 3 (2) 3 (7) 2 (11)
GOSE 3 7 (6) 7 (17) 1 (6)
GOSE 4 10 (8) 10 (24) 1 (6)
GOSE 5 24 (19) 0 (0) 3 (17)
GOSE 6 27 (21) 0 (0) 1 (6)
GOSE 7 11 (9) 0 (0) 1 (6)
GOSE 8 23 (18) 0 (0) 0 (0)
All values are shown as n (%) unless otherwise indicated. a Mean refers to
mean value during first 3 days following admission. CI-DCI Cerebral infarction
due to delayed cerebral ischaemia, DCI Delayed cerebral ischaemia, GOSE
Glasgow Outcome Scale Extended, HR Heart rate, ICH Intracerebral
haematoma, IQR Interquartile range, MAP Mean arterial pressure, NE
norepinephrine, SBP Systolic blood pressure, SD Standard deviation, TCD
Transcranial Doppler, WFNS World Federation of Neurological Surgeons
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fair to moderate, the specificity was high (84 %). Thus,
poor outcome after SAH is multifactorial, and a low
hsTnT does not exempt the patient from a poor progno-
sis but a high hsTnT indicates a high risk of poor out-
come. One could argue that our finding of an
association between increased cardiac biomarkers and
poor long-term outcome is an epiphenomenon. How-
ever, as increased troponins were independently associ-
ated with poor outcome when adjusted for neurological
status upon admission and cerebral infarction we sug-
gest that a causative relationship is possible.
The findings of increased cardiac biomarker levels in
patients with poor neurological long-term outcome were
accompanied by higher heart rates and requirement for
higher doses of catecholamines during the first 3 days
after admission. We have previously shown that
increased levels of hsTnT and NTproBNP are strongly
associated with stress-induced cardiomyopathy after
SAH, which is also described by other groups [28–30].
Thus, the systemic haemodynamics were, most likely,
more compromised in patients with poor neurological
long-term outcome. One could speculate whether such a
haemodynamic instability also impaired cerebral perfu-
sion in these compromised patients, particularly since it
has been suggested that autoregulation of cerebral blood
flow might be impaired in SAH [38]. This is supported
by a recent study showing that patients with increased tro-
ponins had decreased focal and global cerebral perfu-
sion [39]. Both troponin release and a higher heart rate
after SAH are associated with a higher sympathetic tone
[40, 41]. Thus, the higher sympathetic activity, with exces-
sive release of endogenous norepinephrine, and the higher
doses of exogenously administered norepinephrine to the
patients with poor neurological long-term outcome might
have induced a higher cerebral metabolic oxygen demand
compared to patients with good neurological long-term
outcome. Indeed, it has been shown that norepinephrine
increases cerebral metabolism, when the blood–brain bar-
rier is injured, which is seen after SAH [42,43]. Cardiac
dysfunction with haemodynamic instability in combin-
ation with an increased cerebral metabolic demand and
impaired cerebral autoregulation could contribute to a
cerebral oxygen supply/demand mismatch with an in-
creased risk of cerebral infarction. This hypothesis is sup-
ported by our finding that peak hsTnT and NTproBNP
were both independently associated with CT-detected CI-
DCI. However, this finding must be interpreted with cau-
tion, as only 18 patients had CI-DCI. Interestingly,
biomarker-detected myocardial damage was also signifi-
cantly associated with poor long-term outcome even when
adjusting for CT-verified cerebral infarctions. One could
speculate that this could be explained by diffuse cerebral
damage, not detected by ordinary CT scan, due to cerebral
oxygen supply/demand mismatch, causing poor late
neurologic outcome. Future studies should evaluate
whether there is a causal relationship between early re-
lease of biomarkers of myocardial injury after SAH and
late neurological outcome.
The novel finding of this study is that increased troponins
are independently associated with long-term poor outcome
when adjusting for known variables of poor outcome. Pre-
vious studies have shown that increased levels of troponin-I
are associated with death and poor prognosis at 3 months
[1, 12]. BNP and NTproBNP are associated with a worse
short-term outcome and cerebral infarction after SAH [13-
15, 44]. Cardiac complications such as left ventricular re-
gional wall motion abnormalities were associated with cere-
bral infarction and dependent living at 3 months after SAH
in a large recent multicentre study [15], which is also sup-
ported by previous smaller studies [17, 22, 44, 45]. Further-
more, an increased heart rate has been described as being
associated with poor 3-month outcome [46], a finding that
was also demonstrated in the present study. Although most
neurological complications are seen within 3 months after
onset of symptoms, there are several studies reporting that
Fig 2. Peak levels of a high-sensitive troponin T (hsTnT) and b N-
terminal pro B-type natriuretic peptide (NTproBNP) were higher in
patients with poor outcome. Changes in c hsTnT and d NTproBNP over
time are shown. Levels of hsTnT had its peak on day 1 after onset of
symptoms followed by a daily decline both in patients with good and
poor outcome. NTproBNP had its lowest levels on day 1 after onset of
symptoms followed by increased levels the following days. Both hsTnT
and NTproBNP levels were higher in patients with poor outcome. Day
1 refers to first 24 hours after onset of symptoms. *p < 0.05,
**p < 0.01, ***p < 0.001
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patients improve beyond this point [18–20]. Factors associ-
ated with poor long-term outcome are poor neurological
status on admission, cerebral infarction and higher age [47,
48]. These factors are known ominous clinical findings and
were also found to be significantly associated with poor
long-term outcome in the present study. However, no pro-
spective consecutive study has previously reported on the
association between release of cardiac biomarkers or car-
diac complications and long-term outcome. The few
studies available are either non-consecutive, retrospective
or have small sample sizes, and show contradictory results
[21–23]. The finding of the present study—that cardiac
troponin release is independently associated with poor
long-term outcome—gives further support to the notion
that troponin release after SAH is an ominous finding.
The main limitation with this study is the limited
number of patients and the fact that this was a single-
centre study. The relatively low number of patients with
Table 2 Bivariate logistic regression; 1-year poor outcome (GOSE ≤4)
Category Variable OR 95 % CI p value
Background data Age, per year 1.04 1.01–1.07 0.018
Sex 1.01 0.47–2.16 0.976
History of hypertension 1.23 0.57–2.67 0.590
Admission data WFNS grade 4–5 4.99 2.20–11.34 <0.001
Modified Fischer grade 4 2.81 1.27–6.20 0.011
Intracerebral haematoma 3.29 0.98–11.11 0.055
Posterior aneurysm 1.72 0.57–5.20 0.336
Treatment Surgery 1.34 0.54–3.33 0.530
TCD Increased flow velocities 1.41 0.64–3.10 0.398
Cerebral infarction Cerebral infarction, any cause 8.09 3.47–18.84 <0.001
Cardiovascular data SBP on admission 0.99 0.98–1.01 0.474
MAP on admission 0.99 0.96–1.01 0.341
Heart rate on admission 1.01 0.98–1.03 0.652
SBP meana 0.99 0.96–1.02 0.685
Heart rate meana 1.06 1.01–1.11 0.011
Given NE meana, per 0.10 μg/kg/h 1.13 1.01–1.27 0.040
Biomarker data hsTnT peak, per 100 ng/l 1.88 1.28–2.78 0.001
NTproBNP peak, per 1000 ng/l 1.22 1.05–1.42 0.009
aMean refers to mean value during first 3 days following admission. CI Confidence interval, GOSE Glasgow Outcome Scale Extended, hsTnT High-sensitive troponin
T, MAP Mean arterial pressure, NE norepinephrine, NTproBNP N-terminal pro B-type natriuretic peptide, OR Odds ratio, SBP Systolic blood pressure, TCD Transcranial
Doppler, WFNS World Federation of Neurological Surgeons
Table 3 Multivariable regression models; 1-year poor outcome (GOSE ≤4)
Variable OR 95 % CI p value −2LL Sig –2LL change Nagelkerke R2
Model 1 Cerebral infarction, any cause 11.43 4.15–31.5 <0.001 110.28 0.447
WFNS grade 4–5 6.57 2.39–18.04 <0.001
Age, per year 1.05 1.01–1.10 0.009
Model 2 Cerebral infarction, any cause 11.40 3.99–32.57 <0.001 99.05 <0.001 0.528
WFNS grade 4–5 3.58 1.21–10.67 0.022
Age, per year 1.06 1.01–1.10 0.013
hsTnT peak, per 100 ng/l 1.59 1.10–2.29 0.013
Model 3 Cerebral infarction, any cause 9.74 3.48–27.25 <0.001 106.63 0.056 0.462
WFNS 4–5 5.72 2.06–15.87 0.001
Age, per year 1.05 1.01–1.09 0.021
NTproBNP peak, per 1000 ng/l 1.10 0.97–1.24 0.140
−2LL −2 log likelihood, CI Confidence interval, GOSE Glasgow Outcome Scale Extended, hsTnT High-sensitive troponin T, NTproBNP N-terminal pro B-type natriuretic
peptide, OR Odds ratio, WFNS World Federation of Neurological Surgeons
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poor outcome ruled out the possibility of performing a
multivariable analysis in which all variables of interest
were included. However, instead of inappropriately includ-
ing too many variables, we used a clinically relevant model
building. Performing echocardiography in all patients
would have been valuable, as this could have added one
more dimension to the data. The strengths of this study
are the consecutive and prospective design and the num-
ber of patients included in the follow-up (91 %). We also
used the latest assay of troponin measurement, hsTnT,
which has a higher sensitivity and specificity for detecting
cardiac damage than previously used assays. In addition,
high-sensitive assays are recommended by current guide-
lines [49] and hsTnT will probably be the dominating bio-
marker for early detection of myocardial injury.
Conclusion
In conclusion, we found that increased serum levels of
the myocardial injury biomarker hsTnT, when taken
early after admission, is independently associated with poor
1-year neurological outcome in patients with SAH. In
addition, we could demonstrate that increased serum levels
of the cardiac biomarkers hsTnT and NTproBNP are inde-
pendently associated with CI-DCI. These findings further
highlight the importance of increased troponins after SAH.
Future studies should evaluate whether there is a causal re-
lationship between early release of biomarkers of myocar-
dial injury after SAH and late neurological outcome.
Key messages
 Increased serum levels of the myocardial injury
biomarker hsTnT, upon admission, is independently
associated with poor long-term outcome in SAH,
when adjusted for known predictors of poor long-
term outcome.
 Increased serum levels of hsTnT and the myocardial
function biomarker NTproBNP, upon admission, are
Table 4 Bivariate logistic regression; CI-DCI
Category Variable OR 95 % CI p value
Background data Age, per year 0.75 0.95–1.03 0.750
Sex 0.67 0.24–1.93 0.647
History of hypertension 2.00 0.73–5.47 0.177
Admission data WFNS grade 4–5 1.19 0.41–3.44 0.751
Modified Fischer grade 4 2.60 0.94–7.18 0.065
Posterior aneurysm 1.46 0.36–5.90 0.594
Treatment Surgery 0.53 0.13–2.04 0.354
TCD Increased flow velocities 3.89 1.27–11.94 0.017
Cardiovascular data SBP on admission 0.99 0.97–1.01 0.380
MAP on admission 0.98 0.95–1.01 0.289
Heart rate on admission 1.02 0.99–1.05 0.191
SBP meana 0.99 0.95–1.03 0.658
Heart rate meana 1.07 1.00–1.13 0.033
Given NE meana, per 0.10 μg/kg/h 1.14 1.00–1.30 0.048
Biomarker data hsTnT peak, per 100 ng/l 1.23 1.01–1.50 0.040
NTproBNP peak, per 1000 ng/l 1.12 1.02–1.23 0.018
aMean refers to mean value during first 3 days following admission. CI Confidence interval, CI-DCI Cerebral infarction due to delayed cerebral ischaemia, hsTnT
High-sensitive troponin T, MAP Mean arterial pressure, NE norepinephrine, NTproBNP N-terminal pro B-type natriuretic peptide, OR Odds ratio, SBP Systolic blood
pressure, TCD Transcranial Doppler, WFNS World Federation of Neurological Surgeons
Table 5 Multivariable regression models; CI-DCI
OR 95 % CI p value −2LL Sig –2LL change Nagelkerke R2
Model 1 TCD, increased flow velocities 3.84 1.33–11.05 0.013 96.70 0.092
Model 2 TCD, increased flow velocities 3.86 1.31–11.34 0.015 92.73 0.046 0.144
hsTnT peak, per 100ng/l 1.24 1.01–1.53 0.043
Model 3 TCD, increased flow velocities 3.40 1.15–10.04 0.027 91.79 0.026 0.153
NTproBNP peak, per 1000ng/l 1.11 1.00–1.23 0.044
−2LL −2 log likelihood, CI Confidence interval, CI-DCI Cerebral infarction due to delayed cerebral ischaemia, hsTnT High-sensitive troponin T, NTproBNP N-terminal
pro B-type natriuretic peptide, OR Odds ratio, TCD Transcranial Doppler, WFNS World Federation of Neurological Surgeons
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both independently associated with cerebral
infarction due to delayed cerebral ischaemia.
 These findings give further support to the notion
that an early release of the cardiac biomarkers
hsTnT and NTproBNP are ominous findings
associated with neurological sequelae after SAH.
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